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Introduction
Systemic sclerosis (SSc) is a connective-tissue disease
characterized by progressive thickening of the dermis,
often accompanied by insufficiency of internal organs, such
as the lungs, heart, or kidneys [1]. These manifestations are
due to the excessive accumulation of extracellular matrix
proteins, predominantly type I collagen, in the affected
tissues [2]. The cause of SSc is unknown but the early
stage is characterized by a dense mononuclear cell infil-
trate in tissues, suggesting that activation of the immune
system results in the development of tissue fibrosis [3,4].
A prominent humoral abnormality in SSc is manifested by
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The main manifestation of systemic sclerosis (SSc) is the overproduction of extracellular matrix,
predominantly type I collagen. This study was undertaken to evaluate the effects of noncytotoxic doses
of the topoisomerase I inhibitor camptothecin (CPT) on collagen production in the activated dermal
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layers by ELISA and in conditioned media by [3H]proline incorporation, gel electrophoresis, and
autoradiography. Expression of α2(I) collagen (COL1A2) mRNA was measured by northern blot, and
the activity of COL1A2 promoter was determined by a chloramphenicol acetyltransferase assay. CPT
(10–7 M) decreased the deposition of type I collagen by 68%, of type III by 38%, and of type VI by
21% in SSc fibroblasts and to a lesser degree in healthy controls. Similarly, CPT (10–8 M to 10–6 M)
significantly inhibited secretion of newly synthesized collagenous proteins into conditioned media by
50%. CPT (10–8 M to 10–6 M) caused a significant dose-dependent inhibition of COL1A2 mRNA
levels and COL1A2 promoter activity, both by as much as 60%. The inhibitory effect of CPT on
collagen production by fibroblasts from patients with SSc suggests that topoisomerase I inhibitors may
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Keywords: camptothecin, collagen, fibroblast, systemic sclerosis, topoisomerase I
Received: 8 February 2001
Revisions requested: 10 April 2001
Revisions received: 3 July 2001
Accepted: 6 July 2001
Published: 2 August 2001
Arthritis Res 2001, 3:311–318
This article may contain supplementary data which can only be found
online at http://arthritis-research.com/content/3/5/318
© 2001 Czuwara-Ladykowska et al, licensee BioMed Central Ltd
(Print ISSN 1465-9905; Online ISSN 1465-9913)
anti-Topo I = anti-topoisomerase I; BSA = bovine serum albumin; CAT = chloramphenicol acetyltransferase; COL1A2 = type α2(I) collagen; CPT =
camptothecin; DMEM = Dulbecco’s modified Eagle’s medium; ELISA = enzyme-linked immunosorbent assay; FBS = fetal bovine serum; GAPDH =
glyceraldehyde-3-phosphate dehydrogenase; SEM = standard error of the mean; SSc = systemic sclerosis; Topo I = topoisomerase I.
Available online http://arthritis-research.com/content/3/5/311
Arthritis Research    Vol 3 No 5 Czuwara-Ladykowska et al
the presence of anti-nuclear antibodies [5]. The circulating
anti-topoisomerase-I (anti-Topo I; Scl-70) antibodies are
highly specific for SSc [6], and they are found in sera from
30 to 70% of patients [7]. The presence of anti-Topo-I
antibodies is associated with diffuse cutaneous involve-
ment and pulmonary interstitial fibrosis [8] and is consid-
ered a predictive marker of diffuse SSc.
Human DNA topoisomerase I (Topo I) is a 765-amino-acid
nuclear enzyme [9] involved in topological changes of
DNA structure [10]. It plays key roles in DNA replication,
transcription, and recombination. During the Topo I cat-
alytic process, a transient covalent linkage, termed the
‘cleavable complex’, is formed between the enzyme and
DNA strand nicks. Camptothecin (CPT) and its derivatives
specifically target Topo I by binding noncovalently to these
cleavable complexes, stabilizing them and interfering with
DNA religation [11]. As a result of CPT’s action, single-
and double-strand DNA breaks are generated, leading to
premature termination of replication and inhibition of tran-
scription [12]. Cells can repair DNA breaks caused by low
doses of CPT, whereas higher doses lead to cell death
[13]. Since many neoplastic cells are characterized by
high levels and/or activities of Topo I [14,15], this enzyme
has become one of the cellular targets for anticancer
therapy [16,17]. CPT derivatives such as topotecan and
irinotecan (CPT-11) are currently used in the treatment of
various cancers [16–18]. Only limited side effects, such
as manageable neutropenia, in patients who received high
doses of Topo I inhibitors have been reported [16,17].
The mechanism responsible for the production of anti-
Topo-I antibodies in SSc is not fully understood. Recent
studies suggest that activation of Topo-I-reactive T cells is
responsible for the induction and propagation of these
antibodies in SSc patients [19]. At present, the origin of
their target autoantigen is not clear. Significantly, the dis-
appearance of these antibodies, possibly because of
removal of the autoantigen, has been associated with
favorable outcomes [20]. Because of the potential patho-
genic role of Topo I in SSc, we undertook this study to
evaluate the utility of noncytotoxic concentrations of Topo
I inhibitors for the treatment of SSc. We have focused on
the effects of the leading Topo I inhibitor, CPT, on colla-




The subjects were patients with diffuse SSc and healthy
volunteers. The patient group consisted of 18 individuals
(10 women and 8 men) with a mean age of 39.5 ± 2.6
years. All the patients fulfilled the American College of
Rheumatology criteria for the diagnosis of SSc [21]. The
control group were 18 healthy donors with a mean age of
41.0 ± 3.3 years.
Cell culture
Dermal fibroblasts were obtained from clinically affected
skin (on the dorsal forearm) of the SSc patients and from
healthy donors matched with the patients for race, age, and
gender. The control fibroblasts were obtained within
several days of SSc biopsy and were processed in parallel.
For the experiments, cells were starved for 48 h before the
addition of CPT in DMEM/1% fetal bovine serum (FBS).
Reagents
CPT was purchased from Sigma (St Louis, MO, USA) and
dissolved in dimethyl sulfoxide (Sigma). Aliquots of stock
solution (10 mM) were stored at –70°C.
Determination of collagen types and of elastin
production
Collagen and elastin deposition in cell and matrix layers
was determined by solid-phase ELISA with antibodies
against goat anti-collagen I (Chemicon, Temecula, CA,
USA), mouse anti-collagen III (Telios, San Diego, CA,
USA), mouse anti-collagen VI (Telios), or mouse anti-
elastin (Sigma), at dilutions recommended by the manu-
facturers.
To determine the effect of CPT on newly synthesized col-
lagenous proteins, we used an established method of
metabolic labeling with [3H]proline followed by SDS–
PAGE electrophoresis [22]. The results were visualized
by autoradiography. The intensity of bands of collagenous
protein was quantitated using NIH-Image (Densitometry
Software, version 1.55). The effect of CPT on total
protein synthesis was examined using metabolic labeling
with [35S]methionine followed by SDS–PAGE and
autoradiography.
RNA preparation and northern blot analysis
Fibroblasts were treated with CPT at concentrations from
10–9 to 10–6 mol/l for 24 h. Total RNA was extracted and
analyzed by northern blotting as described elsewhere
[23]. Membranes were sequentially hybridized with
radioactive probes for α2(I) procollagen and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and
scanned with a PhosphorImager (Molecular Dynamics,
Inc, Sunnyvale, CA) for mRNA quantitation.
Transient transfection and chloramphenicol
acetyltransferase assays
Transient transfections of normal dermal fibroblasts were
performed with 20 µg of the –353 fragment of α2(I) col-
lagen (COL1A2) promoter linked to the chloramphenicol
acetyltransferase (CAT) reporter gene by the calcium
phosphate/DNA coprecipitation technique as described
elsewhere [24]. CAT values were corrected to reflect the
efficiency of transfection relative to the co-transfected
pSV-β-galactosidase vector (Promega, Madison, WI,
USA).
Statistical analysis
Statistical signifance was evaluated in paired analyses
using the Student’s paired t test or the Wilcoxon test
(nonparametric), depending on the data distribution. Data
values are expressed as means ± SEM. Statistical signifi-
cance was defined as a P value of 0.05 or less (see sup-
plementary material).
Results
Effect of CPT on production of collagen protein
The effect of CPT on the production of types I, III, and VI
collagen by 11 pairs of SSc and normal dermal fibroblasts
was examined by ELISA using fibroblast cell and matrix
layers (Fig. 1a,b,c). Incubation with CPT for 24 h signifi-
cantly decreased the expression of all three collagen
types, although the degree of inhibition varied among the
different collagens. Although CPT at 10–7 mol/l decreased
collagen production more in SSc than in healthy control
fibroblasts (by, respectively, 68% and 48% for type I, 38%
and 15% for type II, and 21% and 7% for type III)
(Fig. a,b,c), these differences were not statistically signifi-
cant. The reduction of type I collagen expression by CPT
after 24 h was also demonstrated by immunocytochem-









The effects of CPT on deposition of collagen types I (a), III (b), and VI (c) and elastin (d) in SSc and healthy control fibroblasts. Fibroblasts were
grown to confluence in 96-well plates and then incubated for 24 h with CPT in DMEM/1% FBS. In control wells (‘None’), the CPT was omitted.
ELISA was performed on the cell and matrix layers with appropriate antibodies as described in the Patients and methods section. Bars show the
relative amounts of collagen types I, III, and VI (a–c) from 11 pairs of SSc and healthy fibroblast cell lines and of elastin (d) from from four pairs of
SSc and healthy fibroblast cell lines. All experiments were done in triplicate. CPT = camptothecin; FBS = fetal bovine serum; SSc = systemic
sclerosis. *P < 0.05, **P < 0.005.
To assess the effect of CPT on production of other extra-
cellular matrix proteins, the effect on elastin was measured
by ELISA: no effect was found in either SSc or control
fibroblasts (Fig. 1d).
The effect of CPT on newly synthesized collagenous pro-
teins secreted into the media was examined in five pairs of
SSc and healthy control fibroblasts in nine independent
experiments. CPT at concentrations from 10–8 to
10–6 mol/l significantly decreased secretion of collage-
nous protein, by up to 50% in both cell types (Fig. 2a,b).
The responsiveness of SSc and healthy control fibroblasts
to different doses of CPT was also compared. No major
differences were observed at the three highest doses
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Figure 2
CPT inhibits secretion of collagenous proteins by both SSc and healthy control fibroblasts. Confluent fibroblasts in 12-well plates were incubated
for 48 h in 0.1% BSA/DMEM containing ascorbic acid (50 µg/ml), and then treated for 24 h with various concentrations of CPT (none, or 10–9,
10–8, 10–7, or 10–6 mol/l). After CPT treatment, 20 µCi/ml of [3H]proline was added to the medium for an additional 24 h. Aliquots of conditioned
media normalized for cell number were loaded on a 6% SDS–polyacrylamide gel. After electrophoresis, the gel was enhanced by fluorography and
visualized by autoradiography. (a) Representative autoradiographs from SSc and healthy control fibroblasts. (b) Summary of quantitative analysis of
the collagenous proteins expressed by SSc (left panel) and healthy control fibroblasts (right panel) after CPT treatment. Bars show means ± SEM
from 10 (SSc) and 9 (healthy) independent experiments. The steady-state level of collagenous proteins in CPT-free controls (‘None’) was arbitrarily
set at 1. (c) Representative autoradiogram of the total protein synthesis in the SSc fibroblasts after CPT treatment. Similar results (not shown) were
obtained with the control cells. BSA= bovine sreum albumin; CPT = camptothecin; SSc = systemic sclerosis. *P < 0.05, **P < 0.005).
used (10–8 to 10–6 mol/l), but SSc fibroblasts appeared to
be slightly more sensitive to the lowest dose of CPT
(10–9 mol/l). Secreted collagenous proteins were inhibited
by 29% ± 0.06 in SSc fibroblasts versus 14% ± 0.03 in
healthy control fibroblasts (P = 0.09). The total protein
synthesis was not affected by CPT treatment, even at the
highest dose used (10–6 mol/l) (Fig. 2c). The number of
cells after CPT treatment was not significantly decreased
(Table 1), indicating that the doses used were not cyto-
toxic to fibroblasts. CPT is cytotoxic mainly to S-phase
cells, and its effects are dependent on cell type [13]. In
general, human fibroblasts are more resistant than neo-
plastic cells or lymphoblasts to DNA-damaging agents
[25]. Although it has been shown that CPT at higher con-
centrations induces cell cycle arrest in proliferating dermal
fibroblasts [26], it is unlikely that the inhibition of collagen









Camptothecin does not affect fibroblast viability
Cell number
CPT concentration (mol/l) NS SD
None (controls) 5904 ± 731 5928 ± 1081
10–9 5614 ± 818 6166 ± 1120
10–8 5424 ± 720 5368 ± 1046
10–7 5051 ± 770 5785 ± 1203
10–6 5142 ± 801 5711 ± 1351
Confluent fibroblasts after 48 h treatment with indicated doses of CPT
were trypsinized and cell number was the mean of two counts using a
Coulter counter. Values are mean cell numbers ± SEM from five SSc
and healthy control pairs after treatment with CPT. CPT = camptothecin;
NS, normal fibroblasts; SD, SSc fibroblasts.
Figure 3
CPT inhibits expression of COL1A2 mRNA in SSc and healthy control fibroblasts. SSc and healthy control cells were incubated with various
concentrations of CPT (10–9 to 10–6 mol/l) and analyzed by northern blotting. (a) Representative northern blot. (b, c) Summary of quantitative
analysis of northern blots from healthy control and SSc cell lines, respectively. All values were corrected for loading differences as determined by
intensity of GAPDH mRNA. Values from the CPT-treated cells indicate band density relative to that of untreated cells (‘None’), which was set at
100. Bars show means ± SEM of the COL1A2/GAPDH ratio from 13 independent experiments using seven different pairs of SSc and healthy
control fibroblasts. COL1A2 = type α2(I) collagen; CPT = camptothecin; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; SSc = systemic
sclerosis. *P < 0.01, **P < 0.005.
experiments were performed with confluent, serum-
starved cells. Taken together, the experiments presented
in this part of the study suggest that CPT is a relatively
specific inhibitor of collagenous protein production in
dermal fibroblasts.
Effect of CPT on expression of COL1A2 mRNA
The effect of CPT on COL1A2 steady-state mRNA levels
was evaluated in seven pairs of SSc and healthy control
dermal fibroblasts in 13 independent experiments. CPT
treatment resulted in a dose-dependent decrease of
COL1A2 mRNA expression levels in SSc and healthy
control fibroblasts as demonstrated by northern blot analy-
sis. Note that GAPDH mRNA levels were not inhibited by
CPT (Fig. 3a). The highest dose of CPT (10–6) resulted in
about 60% inhibition of COL1A2 mRNA levels in both
SSc and healthy control fibroblasts (Fig. 3b,c). These
results suggest that the inhibitory effects of CPT occur, at
least partially, through regulating the levels of expression
of collagen mRNA.
Effect of CPT on activity of COL1A2 promoter
The transcriptional activity of the human COL1A2 pro-
moter fragment (–353) linked to the CAT reporter gene
was examined in transient transfection assays after CPT
treatment. Consistent with the mRNA data, the maximal
inhibition of collagen promoter activity was 60% (Fig. 4),
suggesting that the inhibitory effect of CPT on the
COL1A2 gene occurs at the transcriptional level. As previ-
ously reported, CPT has no effect on the activity of the
control vector [27]. The activity of the collagen promoter
was inhibited by much lower doses of CPT (10–12 and
10–10 mol/l) than those that inhibited collagen mRNA
levels (10–8 to 10–6 mol/l). This probably reflects the differ-
ence in sensitivity to CPT between exogenous and
endogenous promoters due to the protective role of chro-
matin surrounding the endogenous promoter.
Discussion
DNA Topo I is an essential enzyme involved in such crucial
cellular functions as replication and transcription. This
study was undertaken to determine whether inhibition of its
activity by noncytotoxic doses of CPT, a drug that selec-
tively targets Topo I, could reverse the activated phenotype
of fibroblasts from patients with SSc. CPT, an alkaloid that
exists in nature and has been used for centuries in tradi-
tional Chinese medicine, is a prototype of a new class of
anticancer drugs [16]. It is commonly used in in vitro exper-
imental model systems to study the mechanisms of action
of Topo I inhibitors. Clinically approved Topo I inhibitors,
irinotecan and topotecan, are semisynthetic derivatives of
CPT that differ from CPT in toxicity profiles and water solu-
bility but not in the mechanisms of action [16,17].
Our results show that CPT significantly inhibits the synthe-
sis of collagen by dermal fibroblasts from patients with
SSc. The production of types I, III, and VI collagen was
significantly inhibited in SSc and healthy control dermal
fibroblasts without affecting total protein synthesis. The
inhibitory mechanism of CPT was further examined using
COL1A2 as a representative collagen gene. The drug
inhibited COL1A2 steady-state mRNA levels and pro-
moter activity by 60%, indicating that it directly inhibits
transcription of this collagen gene. It is not known why col-
lagen genes, and particularly type I collagen, are more
sensitive to CPT than other genes. The drug either may
directly interfere with the transcription of collagen genes
or may influence signaling pathways that regulate collagen
gene expression.
The role of Topo I in the initiation of transcription has previ-
ously been shown [28]. These previous studies have
revealed that Topo I can act as either an activator or a
repressor, depending on the promoter and the presence
of other transcription factors [29]. It has been proposed
that Topo I may be directly involved in transcription of
interstitial collagen genes [30]. The nucleotide sequences
of these genes contain specific DNA motifs that constitute
high-affinity Topo I binding sites [31]. Three such DNA
motifs reside within the COL1A2 promoter [30]. Further
studies are needed to determine whether Topo I plays a
direct role in the regulation of type I collagen transcription.
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Figure 4
CPT inhibits COL1A2/CAT promoter activity. Human dermal
fibroblasts were transiently transfected with 20 µg of COL1A2/CAT
promoter construct and treated with CPT (at 10–12 to 10–6 mol/l) for
24 h. Samples of cell extracts were normalized for protein
concentration. Comparisons of the promoter transcription activity after
CPT treatment were made between unstimulated and CPT-treated
cells (done in duplicate). Transcriptional activity of the COL1A2/CAT
gene in the CPT-free control (‘None’) was arbitrarily set at 100. Bars
show mean ± SEM from 11 independent experiments (*P < 0.01).
COL1A2 = type α2(I) collagen; CAT = chloramphenicol acetyltransferase;
CPT = camptothecin.
Recently, a new role for CPT has been proposed [32]. It
has been shown to activate transcription factor NF-κB in
various cell types, including a fibroblastic cell line. The
activation of NF-κB by CPT involves degradation of the
cytoplasmic IκBα by the ubiquitin–proteasome pathway.
Topotecan, a clinically approved derivative of CPT,
showed similar effects. The activation of NF-κB by CPT
may be directly related to the mechanism of CPT COL1A2
gene regulation. It has been shown that the inhibitory
effect of TNF-α on COL1A2 gene transcription is medi-
ated via NF-κB [33]. Thus, CPT may inhibit COL1A2 by a
mechanism involving activation of NF-κB. This hypothesis
could be tested using other DNA topoisomerase poisons
known to induce NF-κB [34].
Despite significant progress towards understanding the
pathogenesis of SSc and other fibrotic diseases, effective
treatment is still lacking. Specific compounds that have
the potential to inhibit collagen production such as CPT
and the recently described inhibitor of geranylgeranyl
transferase I [35] may prove to be clinically useful in the
treatment of fibrosis.
Conclusion
In conclusion, our study shows that CPT has a potent
selective inhibitory effect on collagen gene expression;
however, the specific molecular mechanisms of action are
presently not known and will require further study.
The inhibitory effect of CPT on collagen gene expression
suggests that Topo I inhibitors may be an effective treat-
ment for limiting fibrosis in SSc patients.
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Dermal fibroblasts were obtained from patients with
diffuse SSc and healthy volunteers. The patient group
consisted of 18 individuals (10 females and 8 males),
whose mean age was 39.5 ± 2.6 years (range 30–51). All
patients fulfilled the American College of Rheumatology
(formerly American Rheumatism Association) criteria for
the diagnosis of SSc [21]. They were recruited from the
Department of Dermatology, Warsaw Medical School,
Warsaw, Poland, and the Division of Rheumatology and
Immunology, Medical University of South Carolina,
Charleston, SC, USA. All the patients enrolled in the study
had been recently diagnosed with SSc and their disease
duration was between 1 month and 1 year. When the skin
biopsy was performed, patients were not receiving any
treatment known to influence collagen synthesis or depo-
sition. The control group included 18 healthy donors with
a mean age of 41.0 ± 3.3 years (range 23–60). Informed
consent was obtained from patients and healthy donors
before each biopsy was performed.
Cell culture
SSc dermal fibroblast cell lines were established from
biopsy specimens obtained from clinically affected skin
(on the dorsal forearm). Control dermal fibroblasts, from
healthy donors matched for race, age, and gender with
donors of SSc cell lines, were obtained by skin biopsy
within several days of the SSc biopsy and were processed
in parallel. Each biopsy was dissociated enzymatically by
0.25% collagenase type I (Sigma) and 0.05% DNase
(Sigma) in DMEM with 20% fetal bovine serum (FBS)
(HyClone). The fibroblasts were cultured in DMEM con-
taining 10% FBS and 50 µg/ml gentamicin (Sigma). For
experiments, cells were starved in serum-free-medium
(0.1% BSA in DMEM) for 48 h before the addition of CPT
(Sigma) in DMEM/1% FBS. The fibroblasts used for
experiments were from passages three to six.
Reagents
CPT (Sigma) was dissolved in dimethyl sulfoxide (Sigma).
Aliquots of stock solution (10 mM) were stored at –70°C
and diluted further in 1% FBS/DMEM immediately before
each experiment.
Determining production of collagen types I, III, and VI
and of elastin
Fibroblasts (104 cells/well) were seeded in 96-well flat-
bottom culture plates (Costar, Corning, NY, USA) and
treated with CPT for 24 h. Deposition of collagen and
elastin in cell and matrix layers was determined by solid-
phase ELISA with antibodies against goat anti-collagen I
(Chemicon), mouse anti-collagen III (Telios), mouse anti-
collagen VI (Telios), or mouse anti-elastin (Sigma), at dilu-
tions recommended by the manufacturers.
For determination of newly synthesized collagenous pro-
teins, fibroblasts were plated in 12-well plates and grown
to visual confluency. The medium was changed to serum-
free medium (1% BSA/DMEM) supplemented with
50 µg/ml of ascorbic acid for 48 h. Cells were treated with
CPT (from 10–9 to 10–6 mol/l) in the presence of ascorbic
acid for the next 48 h. 20 µCi/ml of [3H]proline (NEN,
Boston, MA, USA) was added during the last 24 h of incu-
bation with CPT. Medium was harvested from each well
and cells were trypsinized and counted. Medium was
dehydrated in a SpeedVac (Savant, Holbrook, NY, USA).
Aliquots of media normalized for cell number were dena-
tured by boiling them in the SDS sample buffer and were
loaded on 6% SDS–polyacrylamide gels. After elec-
trophoresis, gels were enhanced by immersion in 2,5-
diphenyloxazole (PPO) and visualized by autoradiography.
The intensity of collagenous protein bands was quanti-
tated using NIH-Image.
The effect of CPT on total protein synthesis was studied
using metabolic labeling with [35S]methionine followed by
SDS–PAGE and autoradiography. Fibroblasts were
grown to confluence in 12-well plates, starved for 48 h,
and treated with CPT for the next 24 h. After CPT treat-
ment, cells were incubated in methionine-free medium
(Gibco), and 10 µCi/ml of [35S]methionine (NEN) was
added for the next 4 h. Cells were solubilized in RIPA
buffer (50 mM Tris–HCl [pH 8.0], 150 mM NaCl, 0.02%
sodium azide, 0.1% SDS, 100 µg/ml phenylmethylsulfonyl
fluoride, 1% NP-40, 0.5% sodium deoxycholate, and
10 µM sodium orthovanadate). Protein concentrations
were normalized for cell number and separated by 6%
SDS–PAGE.
RNA preparation and northern blot analysis
Fibroblasts were grown to confluence in 10% FBS/DMEM
and then incubated in serum-free medium. The cells were
treated with CPT at concentrations from 10–9 to
10–6 mol/l for 24 h. Total RNA was extracted and analyzed
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by northern blotting as described previously [23]. Mem-
branes were sequentially hybridized with radioactive
probes for α2(I) procollagen and GAPDH and scanned
with a PhosphorImager (Molecular Dynamics, Inc., Sunny-
vale, CA) for mRNA quantitation. SSc and healthy dermal
fibroblast RNA samples were analyzed together.
Assays of transient transfection and chloramphenicol
acetyltransferase
Transient transfections of normal dermal fibroblasts were
performed by the calcium phosphate/DNA coprecipitation
technique as described previously [24]. Briefly, the cells
were grown to 70% confluence in 100-mm2 dishes in
10% FBS/DMEM and were transfected with 20 µg of
plasmid DNA containing the –353 fragment of the colla-
gen α2(I) promoter linked to the CAT reporter gene (-353
COL1A2/CAT construct). The pSV-β-galactosidase
control vector (Promega) (2.5 µg) was co-transfected to
allow normalization for transfection efficiency. The day
after transfection, cells were treated with CPT (at concen-
trations from 10–12 to 10–6 mol/l), and incubation was con-
tinued for the next 24 h. CAT assays were performed as
described previously [24]. Cell extracts normalized for
protein concentration were used to measure CAT activity,
and the values obtained were corrected to reflect the effi-
ciency of transfection relative to the co-transfected pSV-β-
galactosidase vector.
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